Your browser doesn't support javascript.
loading
Clinicopathological investigation of the background of cognitive decline in elderly schizophrenia.
Miwa, Ayako; Hirano, Mitsuaki; Torii, Youta; Sekiguchi, Hirotaka; Habuchi, Chikako; Fujishiro, Hiroshige; Yoshida, Mari; Iwai, Kiyoshi; Kawashima, Kunihiro; Iritani, Shuji.
Affiliation
  • Miwa A; Moriyama General Mental Hospital, Aichi, Japan.
  • Hirano M; Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan.
  • Torii Y; Moriyama General Mental Hospital, Aichi, Japan.
  • Sekiguchi H; Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan.
  • Habuchi C; Okehazama Hospital Fujita Mental Care Center & the Neuroscience Research Center, Aichi, Japan.
  • Fujishiro H; Aichi Psychiatric Medical Center, Aichi, Japan.
  • Yoshida M; Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan.
  • Iwai K; Kawasaki Memorial Hospital, Kanagawa, Japan.
  • Kawashima K; Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan.
  • Iritani S; Moriyama General Mental Hospital, Aichi, Japan.
Acta Neuropsychiatr ; 33(2): 85-91, 2021 Apr.
Article in En | MEDLINE | ID: mdl-33143788
ABSTRACT

OBJECTIVE:

We have often observed dementia symptoms or severe neurocognitive decline in the long-term course of schizophrenia. While there are epidemiological reports that patients with schizophrenia are at an increased risk of developing dementia, there are also neuropathological reports that the prevalence of Alzheimer's disease (AD) in schizophrenia is similar to that in normal controls. It is difficult to distinguish, based solely on the clinical symptoms, whether the remarkable dementia symptoms and cognitive decline seen in elderly schizophrenia are due to the course of the disease itself or a concomitant neurocognitive disease. Neuropathological observation is needed for discrimination.

METHODS:

We conducted a neuropathological search on three cases of schizophrenia that developed cognitive decline or dementia symptoms after a long illness course of schizophrenia. The clinical symptoms of total disease course were confirmed retrospectively in the medical record. We have evaluated neuropathological diagnosis based on not only Hematoxylin-Eosin and Klüver-Barrera staining specimens but also immunohistochemical stained specimens including tau, ß-amyloid, pTDP-43 and α-synuclein protein throughout clinicopathological conference with multiple neuropathologists and psychiatrists.

RESULTS:

The three cases showed no significant pathological findings or preclinical degenerative findings, and poor findings consistent with symptoms of dementia were noted.

CONCLUSION:

Although the biological background of dementia symptoms in elderly schizophrenic patients is still unclear, regarding the brain capacity/cognitive reserve ability, preclinical neurodegeneration changes in combination with certain brain vulnerabilities due to schizophrenia itself are thought to induce dementia syndrome and severe cognitive decline.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Brain / Dementia / Cognitive Dysfunction / Neuropathology Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Acta Neuropsychiatr Year: 2021 Document type: Article Affiliation country: Japón

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Brain / Dementia / Cognitive Dysfunction / Neuropathology Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Acta Neuropsychiatr Year: 2021 Document type: Article Affiliation country: Japón